Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and cognitive function

This article was originally published in The Tan Sheet

Executive Summary

Low-dose aspirin use does not protect older women from cognitive decline, according to a randomized, double-blind study published on the British Medical Journal's Web site April 27. Conducted by Jae Hee Kang, et al., Brigham and Women's Hospital in Boston, the nearly 10-year study evaluated 6,377 women aged 65 and older who were taking part in the Women's Health study. Subjects were divided into two treatment groups: low-dose aspirin and placebo. Cognitive performance measured at 5.6 years and 9.6 years of treatment were similar among the groups. Although results suggest category fluency was better in the aspirin group, authors stress the finding should be interpreted "with caution," concluding "other methods for preserving cognitive function in older people need to be investigated." A study in the April 18 issue of the Journal of the National Cancer Institute and a recent Consumers Union report finds aspirin use was associated with decreased risks of certain cancers and heart attack, respectively (1"The Tan Sheet" April 23, 2007, p. 8 and 2"The Tan Sheet" April 23, 2007, p. 10)...

You may also be interested in...



Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union

Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Topics

UsernamePublicRestriction

Register

PS100439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel